Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pd-0166285. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 9/20 | 0.97 |
| ▸ | SRC known ✓ | P12931 | 6/20 | 0.97 |
| ▸ | PDGFRB known ✓ | P09619 | 3/20 | 0.97 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.97 |
| ▸ | RIPK2 | O43353 | 8/20 | 0.97 |
| ▸ | NOD2 | Q9HC29 | 8/20 | 0.97 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.97 |
| ▸ | WEE1 | P30291 | 4/20 | 0.97 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.97 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.97 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.97 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.97 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.97 |
| ▸ | JAK2 | O60674 | 1/20 | 0.97 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.97 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.97 |
| ▸ | PAK4 | O96013 | 1/20 | 0.97 |
| ▸ | ABL1 | P00519 | 1/20 | 0.97 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.97 |
| ▸ | LCK | P06239 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pd-0166285 SCHEMBL29658286 | 1.00 | FGFR1 (0.97) | FGFR1RIPK2NOD2ACVR1SRC | |
| Pd-0166285 SCHEMBL15106017 | 0.99 | FGFR1 (0.98) | FGFR1RIPK2NOD2ACVR1SRC | |
| Pd-0166285 SCHEMBL30276696 | 0.99 | FGFR1 (0.98) | FGFR1RIPK2NOD2ACVR1SRC | |
| Pd-0166285 SCHEMBL133914 | 0.98 | FGFR1 (1.00) | FGFR1RIPK2NOD2ACVR1SRC | |
| Pd-0166285 SCHEMBL30250248 | 0.98 | FGFR1 (1.00) | FGFR1RIPK2NOD2ACVR1SRC | |
| SCHEMBL10108147 | 0.94 | FGFR1 (0.91) | FGFR1RIPK2NOD2ACVR1SRC | |
| SCHEMBL10108496 | 0.93 | FGFR1 (0.89) | FGFR1RIPK2NOD2ACVR1SRC | |
| SCHEMBL20563458 | 0.90 | RIPK2 (1.00) | FGFR1RIPK2NOD2ACVR1SRC | |
| SCHEMBL29498246 | 0.90 | RIPK2 (1.00) | FGFR1RIPK2NOD2ACVR1SRC | |
| Hydrochloric Acid SCHEMBL5763427 | 0.89 | FGFR1 (0.81) | FGFR1RIPK2NOD2ACVR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-19 | — | — | US | claimed |
| CN-114340733-A | Regeneration of connective tissue function and phenotype by Npas2 inhibition | 加利福尼亚大学董事会 | 2022-04-12 | — | — | CN | claimed |
| US-20180291448-A1 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2018-10-11 | — | — | US | claimed |
| EP-2951290-B1 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) | US HEALTH (US) | 2017-11-29 | — | — | EP | claimed |
| EP-2951290-A2 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2015-12-09 | — | — | EP | claimed |
| WO-2014121077-A2 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-08-07 | — | — | WO | claimed |
| US-20260041817-A1 | BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4346928-B1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | US HEALTH (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250340836-A1 | METHODS FOR PRODUCTION OF IPSCS | NEW YORK STEM CELL FOUND INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250197802-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE U.S.A, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | US | disclosed |
| EP-3793561-B1 | METHOTREXATE COMPOUNDS FOR USE IN TREATING HIV INFECTIONS | NAT CENTRE FOR CELL SCIENCE (IN) | 2025-03-26 | — | — | EP | disclosed |
| US-12258360-B2 | Compositions and methods for treatment of anticancer-drug resistant cancers | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-03-25 | — | — | US | disclosed |
| US-12241083-B2 | Macs-based purification of stem cell-derived retinal pigment epithelium | FUJIFILM Cellular Dynamics, Inc. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3323884-A1 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) | The United States Of America as Represented by the Secretary, Department of Health an Human Service (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-2951290-B1 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) | US HEALTH (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2017044483-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044488-A1 | MACS-BASED PURIFICATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM | CELLULAR DYNAMICS INTERNATIONAL, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170067017-A1 | MACS-BASED PURIFICATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM | CELLULAR DYNAMICS INTERNATIONAL, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| EP-2951290-A2 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014121077-A2 | METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | PER2, NCBP2, NOTCH1 | FGFR1 3850/4885SRC 4695/4885PDGFRB 3575/4885 |
| US-12258360-B2 | Compositions and methods for treatment of anticancer-drug resistant cancers | TP53, ANXA5, MCL1 | FGFR1 4024/4885SRC 330/4885PDGFRB 2156/4885 |
| US-20260041817-A1 | BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE | LGALS1, LGALS9, ALDH1A2 | FGFR1 499/4885SRC 4376/4885PDGFRB 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.